Cortés-Funes Castro, Hernán Hitt Sabag, Ricardo
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. [artículo] - Annals of Oncology, 2012 - 23(4):1016-22.
Formato Vancouver:
Hitt R, Irigoyen A, Cortés-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernández JJ, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of
patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012 Apr;23(4):1016-22.
PMID: 21865152
Contiene 34 referencias
The efficacy and safety of a novel combination of weekly paclitaxel and the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck were investigated.
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. [artículo] - Annals of Oncology, 2012 - 23(4):1016-22.
Formato Vancouver:
Hitt R, Irigoyen A, Cortés-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernández JJ, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of
patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012 Apr;23(4):1016-22.
PMID: 21865152
Contiene 34 referencias
The efficacy and safety of a novel combination of weekly paclitaxel and the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck were investigated.
